Dita Gratzinger, MD, Pathology, Stanford, CA, Lucile Packard Children's Hospital Stanford

DitaGratzingerMDPhD

Pathology • Stanford, CA

Hematopathology, Anatomic Pathology

Associate Professor, Pathology, Stanford University Medical Center

Join to view full profile

Dr. Gratzinger is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gratzinger's full profile

Already have an account?

Summary

  • I am an academic hematopathologist with a broad clinical practice including adult and pediatric bone marrow, blood, lymph node and flow cytometry. I am involved in training residents and fellows as part of my daily practice. I have significant translational research interests in the interaction of stroma and vasculature with hematopoietic malignancy, including myelodysplastic syndromes and lymphoma.

Education & Training

  • Stanford University
    Stanford UniversityFellowship, Hematopathology, 2006 - 2007
  • Stanford University
    Stanford UniversityFellowship, Surgical Pathology, 2005 - 2006
  • Stanford University
    Stanford UniversityResidency, Anatomic and Clinical Pathology, 2003 - 2006
  • Yale University School of Medicine
    Yale University School of MedicineClass of 2003

Certifications & Licensure

  • NV State Medical License
    NV State Medical License 2013 - 2021
  • CA State Medical License
    CA State Medical License 2004 - 2022
  • American Board of Pathology Pathology - Anatomic
  • American Board of Pathology Hematopathology

Publications & Presentations

PubMed

Press Mentions

  • Corrigendum to “KB004, a First in Class Monoclonal Antibody Targeting the Receptor Tyrosine Kinase EphA3, in Patients with Advanced Hematologic Malignancies: Results from a Phase 1 Study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]
    Corrigendum to “KB004, a First in Class Monoclonal Antibody Targeting the Receptor Tyrosine Kinase EphA3, in Patients with Advanced Hematologic Malignancies: Results from a Phase 1 Study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]August 25th, 2017

Hospital Affiliations

Dr. Dita Gratzinger, Dr. Dita Gratzinger, MD, Dr. D Gratzinger